Recent

% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

  • left2rightdoor left2rightdoor Nov 8, 2012 11:17 AM Flag

    General immunotherapy benefit

    So does this mean Allovectin is like an adjuvant for other immunotherapies as well as its own effects
    Allovectin(R) produces a marked anti-tumor effect in the mouse melanoma model stronger than that produced by any of the evaluated antibodies;
    Combination approaches using Allovectin(R) with each of the antibodies produce additive to synergistic effects; the best results in the mouse melanoma model are with the combination of Allovectin(R) and anti-CTLA-4 antibody; and

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Not to beat my own drum, but I predicted this should be the case before I became aware of these experiments. If A-7 works in the way it is proposed to, these results almost have to follow.

      "Vical announces preclinical data support potential combinations for Allovectin with emerging immunotherapies (VICL) 3.15 : Co announced the release of animal data at a melanoma conference documenting the benefits of combining the co's Allovectin immunotherapy with anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies, which are emerging immunotherapies for metastatic melanoma. The co also announced a new publication supporting Allovectin's proposed mechanisms of action. Conclusions from studies are: Allovectin produces a marked anti-tumor effect in the mouse melanoma model stronger than that produced by any of the evaluated antibodies; combination approaches using Allovectin with each of the antibodies produce additive to synergistic effects; the best results in the mouse melanoma model are with the combination of Allovectin and anti-CTLA-4 antibody; and the data, which support the distinct but complementary mechanisms of action of these immunotherapies, warrant further evaluation in humans."

      The fact that they see it in the anti-CTLA4 (read BMY's Yervoy), anti-PD-1 (read BMY's MDX-1106), and anti-PD-L1 (read Genetech's antibody, sorry for the momentary lapse) can be read as three independent validations. Have to see the actual data, I have not. If A7 stimulates the expected response, these biologics all are supposed to act on down stream components of that system. It is not a matter of one being an adjuvant for the other as much as them working in concert on different elements of the response.

 
VICL
3.19-0.06(-1.85%)Sep 26 3:58 PMEDT